|
Jul 2025
As of Jul 21, 2025
|
Mar 2024
As of Mar 31, 2024
|
Mar 2023
As of Mar 31, 2023
|
Mar 2022
As of Mar 31, 2022
|
Mar 2021
As of Mar 31, 2021
|
Mar 2020
As of Mar 31, 2020
|
Mar 2019
As of Mar 31, 2019
|
Mar 2018
As of Mar 31, 2018
|
|
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | ||||||||
| Prepaid expenses and other receivables | ||||||||
| Convertible note receivable | ||||||||
| Total current assets | ||||||||
| Investment in associate | ||||||||
| Investment in public company | ||||||||
| Goodwill | ||||||||
| In-process research and development | ||||||||
| Deferred commitment fee, net of amortization of $900 and $61, respectively | ||||||||
| Right-of-use asset | ||||||||
| Other assets, including equipment, net | ||||||||
| Total non-current assets | ||||||||
| Total assets | ||||||||
| Liabilities and Equity (Deficit) | ||||||||
| Current liabilities | ||||||||
| Accounts payable and accrued liabilities | ||||||||
| Lease liability - current, including interest | ||||||||
| Other current liabilities | ||||||||
| Total current liabilities | ||||||||
| Non-current liabilities | ||||||||
| Lease liability - non-current | ||||||||
| Warrant liability | ||||||||
| Deferred tax liability | ||||||||
| Deferred purchase price payable - Tarus | ||||||||
| Deferred obligation - iOx milestone | ||||||||
| Total non-current liabilities | ||||||||
| Total liabilities | ||||||||
| Shareholders’ Equity (Deficit) | ||||||||
| Capital stock | ||||||||
| Share option reserve | ||||||||
| Accumulated other comprehensive loss | ||||||||
| Accumulated deficit | ||||||||
| Total equity (deficit) attributable to owners of the Company | ||||||||
| Non-controlling interest | ||||||||
| Total equity (deficit) | ||||||||
| Total liabilities and equity (deficit) | ||||||||
Loading...
